Mr Leslie S Jones, RPH | |
13525 Pacific Breeze Dr, Santa Rosa Valley, CA 93012-8951 | |
(805) 523-2002 | |
Not Available |
Full Name | Mr Leslie S Jones |
---|---|
Gender | Male |
Speciality | Pharmacist |
Location | 13525 Pacific Breeze Dr, Santa Rosa Valley, California |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1740400209 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
183500000X | Pharmacist | 30199 (California) | Primary |
Mailing Address | Practice Location Address |
---|---|
Mr Leslie S Jones, RPH 13525 Pacific Breeze Dr, Santa Rosa Valley, CA 93012-8951 Ph: (805) 523-2002 | Mr Leslie S Jones, RPH 13525 Pacific Breeze Dr, Santa Rosa Valley, CA 93012-8951 Ph: (805) 523-2002 |
News Archive
Researchers from Mount Sinai School of Medicine have for the first time developed a way to visualize coronary artery plaques vulnerable to rupture using multi-color computed tomography (CT), an innovation that will lead to better and earlier diagnosis of cardiovascular disease. The data are published in the September issue of Radiology.
Researchers detect cancer cells at an early stage of development via luminescent nanothermometers
The N.H. House has voted to form an interstate health care compact, rejecting an effort to instead study the cost implications for New Hampshire if the state assumed control for health care within its boundaries. Under the bill, the states would receive block grants from the federal government and would take over Medicare and Medicaid.
Teenaged boys from well-off Chinese families who say they are physically active and eat plenty of vegetables but few sweets are more likely to be overweight, according to a study led by researchers at the Keck School of Medicine of the University of Southern California.
Forest Laboratories, Inc. and Gedeon Richter Plc. today announced preliminary top-line results from an 8-week Phase II clinical trial of the novel, investigational antipsychotic agent cariprazine for the treatment of bipolar depression. Cariprazine is currently undergoing Phase III trials for separate indications of schizophrenia and bipolar mania.
› Verified 2 days ago